The chemotherapy-induced nausea and vomiting (cinv) global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Chemotherapy-Induced Nausea and Vomiting (CINV) Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size —
The chemotherapy-induced nausea and vomiting (cinv) market size has grown strongly in recent years. It will grow from $2.69 billion in 2023 to $2.92 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to growth in chemotherapy use, improved antiemetic agents, clinical guidelines, patient advocacy.
The chemotherapy-induced nausea and vomiting (cinv) market size is expected to see strong growth in the next few years. It will grow to $3.88 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to personalized medicine, advances in antiemetic agents, telehealth and remote monitoring, health equity initiatives. Major trends in the forecast period include combination antiemetic therapies, supportive care services, digital health tools, survivorship care.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report
Scope Of Chemotherapy-Induced Nausea and Vomiting (CINV) Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
Market Drivers –
The increasing prevalence of cancer is expected to propel the growth of chemotherapy-induced nausea and vomiting (CINV) market going forward. Cancer is when some cells in the body develop uncontrolled and spread to other body regions. As cancer cases continue to grow, there is a greater incentive to develop more effective and targeted anti-emetic treatments to alleviate CINV, a distressing side effect of chemotherapy. This heightened focus on CINV management has led to advancements in understanding its underlying mechanisms and developing novel therapies. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based volunteer health organization committed to cancer eradication, in the United States, it is anticipated to be 1.9 million new cancer cases (approximately 5,370 cases per day) and 609,820 cancer deaths (about 1,670 deaths per day) in 2023. Therefore, the increasing prevalence of cancer will drive the chemotherapy-induced nausea and vomiting (CINV) market.
Market Trends —
Major companies operating in the chemotherapy-induced nausea and vomiting (CINV) market are working on new product innovations, such as transdermal delivery systems (TDS), to meet the customer requirements in the market. A transdermal delivery system (TDS) is a drug delivery system that allows the controlled release of a medication through the skin for systemic absorption. For instance, in April 2021, Starton Therapeutics Inc., a US-based biotechnology company, announced the FDA approval for STAR-OLZ transdermal delivery system (TDS) to treat chemotherapy-induced nausea and vomiting (CINV). STAR-OLZ is a multi-day olanzapine transdermal delivery system (TDS) covering the duration of the five-day CINV therapy. Independent double-blind trials have revealed that olanzapine is a potent antiemetic, outperforming other standard-of-care therapies, including NK1 receptor antagonists, regarding nausea management. STAR-OLZ previously completed Phase 1 in-human bioavailability (BA) trials, demonstrating that the transdermal patch has acceptable local tolerability during a 5-day dosing interval and provides roughly 60% less medication than the oral version.
The chemotherapy-induced nausea and vomiting (cinv) market covered in this report is segmented –
1) By Form: Injectables; Oral; Transdermal Patches
2) By Drug Class: 5-HT3 Receptor Antagonists; Neurokinin-1 Receptor Antagonists; Corticosteroids; Cannabinoids; Other Drug Class
3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC); Moderately Emetogenic Chemotherapy (MEC); Low Emetogenic Chemotherapy (LEC)
4) By Distribution Channel: CINV Hospitals; Cancer Research Institute; Retail Pharmacies; Online Pharmacies; Drug Stores
5) By Application: Gynecology; Urology; Gastrointestinal Surgery; Other Applications
Get an inside scoop of the chemotherapy-induced nausea and vomiting (cinv) market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp
Regional Insights —
North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2023. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies —
Major players in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.
Table of Contents
1. Executive Summary
2. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report Structure
3. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Trends And Strategies
4. Chemotherapy-Induced Nausea and Vomiting (CINV) Market — Macro Economic Scenario
5. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size And Growth
…..
27. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
